Invest and Sell Synchron Stock

Synchron stock price

Forge Price ¹

Price not yet available

Last Closed Trade ²

Close Date

xx/xx/xx

Last Closed Trade Price

$xx.xx

Last Funding Round (LFR)

Date

xx/xx/xx

Price per Share

$xx.xx

Access Stock Price

Synchron funding rounds and valuation

Funding history chart

Funding round details

	Funding Date	Share Class	Amount Raised	Price per Share	Post-Money Valuation	Key Investors
	12/15/2022	Series C	$74.13MM	$xx.xx	$400.53MM	Alumni Ventures, Arch Venture Partners, Bezos Expeditions, Forepoint Capital Partners, Gates Frontier, Greenoaks, Id8 Investments, Khosla Ventures, Metis, Moore Strategic Ventures, Neurotechnology Investors, Project X, Reliance Digital Health Limited, Shanda Group, University Of Melbourne
Price per Share $xx.xx Shares Outstanding 2,657,210 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 8.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors Alumni Ventures, Arch Venture Partners, Bezos Expeditions, Forepoint Capital Partners, Gates Frontier, Greenoaks, Id8 Investments, Khosla Ventures, Metis, Moore Strategic Ventures, Neurotechnology Investors, Project X, Reliance Digital Health Limited, Shanda Group, University Of Melbourne
	12/15/2022	Series C-1	$872,072.00	$xx.xx	$400.53MM	Alumni Ventures, Arch Venture Partners, Bezos Expeditions, Forepoint Capital Partners, Gates Frontier, Greenoaks, Id8 Investments, Khosla Ventures, Metis, Moore Strategic Ventures, Neurotechnology Investors, Project X, Reliance Digital Health Limited, Shanda Group, University Of Melbourne
Price per Share $xx.xx Shares Outstanding 36,777 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 8.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors Alumni Ventures, Arch Venture Partners, Bezos Expeditions, Forepoint Capital Partners, Gates Frontier, Greenoaks, Id8 Investments, Khosla Ventures, Metis, Moore Strategic Ventures, Neurotechnology Investors, Project X, Reliance Digital Health Limited, Shanda Group, University Of Melbourne
	06/03/2021	Series B	$36MM	$xx.xx	$139.83MM	Arani Bose, Forepont Capital Partners, General Advance, Id8 Investments, Khosla Ventures, Metis, Neurotechnology Inestors, Re.Mind Capital, Shanda Group, Subversive Capital, Thomas Reardon, University Of Melbourne
Price per Share $xx.xx Shares Outstanding 2,849,155 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 8.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors Arani Bose, Forepont Capital Partners, General Advance, Id8 Investments, Khosla Ventures, Metis, Neurotechnology Inestors, Re.Mind Capital, Shanda Group, Subversive Capital, Thomas Reardon, University Of Melbourne
	06/03/2021	Series B-1	$3.87MM	$xx.xx	$139.83MM	Arani Bose, Forepont Capital Partners, General Advance, Id8 Investments, Khosla Ventures, Metis, Neurotechnology Inestors, Re.Mind Capital, Shanda Group, Subversive Capital, Thomas Reardon, University Of Melbourne
Price per Share $xx.xx Shares Outstanding 360,658 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 8.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors Arani Bose, Forepont Capital Partners, General Advance, Id8 Investments, Khosla Ventures, Metis, Neurotechnology Inestors, Re.Mind Capital, Shanda Group, Subversive Capital, Thomas Reardon, University Of Melbourne
	04/04/2017	Series A	$3.54MM	$xx.xx	$14.16MM	Darpa, Neurotechnology Investors
Price per Share $xx.xx Shares Outstanding 1,770,224 Liquidation Pref Order 1 Liquidation Pref As Multiplier 1.0x Conversion Ratio 1.0x Dividend Rate 8.0% Cumulative Non-cumulative Participating Non-participating Participation Cap -- Key Investors Darpa, Neurotechnology Investors

Access Stock Price

Synchron stock FAQs

To buy and sell Synchron stock

Can you buy Synchron stock?

As Synchron is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Synchron, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.

How to buy Synchron stock?

To invest in a private company like Synchron through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

Create a free account to access Forge’s marketplace.
Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.

Can you sell Synchron stock?

Yes, you may sell the Synchron stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.

How to sell Synchron stock?

If you hold private company shares of Synchron – whether as an employee or an early investor – Forge can help you sell them.

Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
Indicate your interest to sell your Synchron on our platform.
Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.

To learn more about Synchron stock

Is Synchron a public company?

No, Synchron is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.

What is Synchron’s stock price?

Synchron is a privately held company and therefore does not have a public stock price. However, you may access Synchron private market stock price with Forge Data.

What is Synchron’s stock ticker symbol?

Synchron does not have an official ticker symbol because this company is not currently publicly traded.

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Leadership and board

Leadership

Thomas Oxley Ph.D

Co-Founder, Chief Executive Officer & Board Member

Nicholas Opie Ph.D

Co-Founder, Chief Technology Officer & Board Member

Amos Meltzer

Chief Legal Officer

Rahul Sharma

Co-Founder & Board Member

J Mocco

Chief Medical Officer

Kurt Haggstrom

Chief Commercial Officer

Connie Rey

Vice President, Clinical Affairs

Gary Castro

Vice President, Finance

Riki Banerjee

Vice President, Research & Development

Board

Alexander Morgan Ph.D

Khosla Ventures

Ari Nowacek Ph.D

ARCH Venture Partners

Martin Dieck

NeuroTechnology Investors

Robert Nelsen

ARCH Venture Partners

Josh Duyan

Artisan Partners

Synchron news and media highlights

Mass Device 09/30/2024

Synchron reports positive results from Command study of its BCI system

Brain-computer interface (BCI) developer Synchron today said there were no serious adverse events in its 12-month Command study, which also showed reliable performance of the Stentrode implant. Synchron won FDA breakthrough device designation for the endovascular brain implant in 2020. The Command study is the first investigational device exemption (IDE) trial of a permanently implanted BCI, evaluating safety and efficacy in six patients with severe paralysis.

CNBC 07/16/2024

Brain implant patient says OpenAI’s tech helps him communicate with family

A 64-year-old named Mark has spent the last year learning how to control devices like his laptop and phone using a brain implant. And thanks to OpenAI, it’s gotten a whole lot easier to do. The neurotech startup Synchron said Thursday it’s using OpenAI’s latest artificial intelligence models to build a new generative chat feature for patients with its brain-computer interface, or BCI. Synchron’s model is designed to help people with paralysis communicate and maintain some independence by controlling smartphones, computers and other devices with their thoughts.

Business Wire 04/08/2024

Synchron Launches Patient Registry for Stentrode Brain Computer Interface

Synchron, the brain-computer interface (BCI) company developing endovascular technology to restore functionality in patients with motor impairment, today announced the launch of a community-centered BCI registry to bring patients, carers and clinicians together to learn how BCI is being designed to provide benefit to people with limited mobility. Synchron’s BCI technology is designed to decipher the neural code of the brain and find new ways to restore motor intent to control digital devices.

Medical Device Network 03/21/2023

Synchron to start patient enrolment in brain-computer interface study

Synchron, an endovascular brain-computer interface (BCI) firm, has begun patient enrolment for its COMMAND study. The study will assess the safety and efficacy of the Synchron Switch, a BCI device that helps people with limited mobility operate technology using their thoughts. The device is implanted using a minimally-invasive procedure and the study will evaluate its impact on daily tasks such as texting, emailing, and online shopping.

Other companies like Synchron in the Medical Devices sector

Sector: Healthcare

Subsector: Medical Devices

					Last Funding Round
Company		Forge Price	Forge Price Change ⁵	Last Closed Trade	Share Class	Post-Money Valuation	Price per Share	Amount Raised
	AliveCor	--	--	$xx.xx	Series F	$943.68MM	$xx.xx	$150MM
	CMR Surgical	--	--	$xx.xx	--	--	--	--
	Cresilon	--	--	$xx.xx	Series A-5	$336.88MM	$xx.xx	$25MM
	HistoSonics	--	--	$xx.xx	Series D-1	$598.27MM	$xx.xx	$102.7MM
	Imperative Care	--	--	$xx.xx	Series E-3	$1.66B	$xx.xx	$25MM
	Neuralink	$52.86	-7.51%	$xx.xx	Series D	$3.49B	$xx.xx	$323.24MM
	Ottobock	--	--	$xx.xx	--	--	--	--
	Stimwave	--	--	$xx.xx	Series E	$235.28MM	$xx.xx	$3.27MM
	Therabody	--	--	$xx.xx	--	--	--	--
	ZAP Surgical Systems	--	--	$xx.xx	--	--	--	--

See All Companies

Forge is your trusted partner to buy and sell Synchron stock

Forge is the trusted platform for buying and selling private company stock. Investors and shareholders worldwide rely on our deep data insights, liquidity solutions, and tailored investment opportunities to navigate the private market. Register to get started.

First time buying private market stock?

New to selling your private company stock?

Updated on: Feb 13, 2025

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge. Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company. The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.
The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.
Post-Money Valuation represents the estimated valuation based on company-submitted Certificates of Incorporations (COIs).
Last Known Valuation represents a valuation gathered from non-COI, publicly available sources including company press releases or multiple concurring news articles.
The dollar-figure and percentage displayed indicates the per share change in dollar amount and percentage since the most recent Forge Price change. Percentages are rounded to the nearest whole number.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

The news articles displayed on this page may be curated using artificial intelligence (AI) technology, which selects relevant content from a list of trusted web sources. While we strive for accuracy and reliability, the inclusion of an article does not imply endorsement or verification of its content. This communication is for informational purposes only. Investors should conduct their own research and consult a financial professional before making investment decisions.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.

Synchron stock